Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, Dec. 4, 2013, 189 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $160.56 to $35,901,027,172.20. Highlighted Stocks Traded by Insiders: Akorn (AKRX) - FREE Research Report Abramowitz Kenneth who is Director at Akorn sold 5,000 shares at $25.35 on Dec. 4, 2013. Following this transaction, the Director owned 21,057 shares meaning that the stake was reduced by 19.19% with the 5,000-share transaction. The shares most recently traded at $25.37, up $0.02, or 0.09% since the insider transaction. The average volume for Akorn has been 763,100 shares per day over the past 30 days. Akorn has a market cap of $2.4 billion and is part of the health care sector and drugs industry. Shares are up 88.17% year-to-date as of the close of trading on Wednesday. Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, hospital drugs, and injectable pharmaceuticals in the United States and internationally. The company has a P/E ratio of 62.9. Currently there are 6 analysts that rate Akorn a buy, no analysts rate it a sell, and 1 rates it a hold. Exclusive Offer: Get the latest Stock Analysis on AKRX - FREETheStreet Quant Ratings rates Akorn as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Akorn Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.